3:26 PM - 3:47 PM

[3W9-p-5] Development of a long-acting thioredoxin using albumin fusion technology and its application in refractory lung disease treatment

〇Hiroshi Watanabe^1,2, Ryota Tanaka¹, Yu Ishima^1,2, Victor Chuang³, Masaki Otagiri^4,5, Toru Maruyama^1,2 (1.Dept. of Biopharm., Sch. of Pharm., Kumamoto Univ., 2.Cent. for Clin. Pharm. Sci., Sch. of Pharm., Kumamoto Univ., 3.Fac. of Health Sci., Sch. of Pharm., Curtin Univ., Australia, 4.Sch. of Pharm., Sojo Univ., 5.DDS Res. Inst., Sojo Univ.)

チオレドキシン, アルブミン融合, 酸化ストレス, 炎症, MIF